Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 33.7% in February

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 748,700 shares, a drop of 33.7% from the February 13th total of 1,130,000 shares. Based on an average daily trading volume, of 56,200 shares, the short-interest ratio is currently 13.3 days. Approximately 3.5% of the company’s stock are short sold.

Analyst Ratings Changes

ACRV has been the topic of several research analyst reports. KeyCorp assumed coverage on shares of Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating on the stock. Cantor Fitzgerald started coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They set an “overweight” rating for the company. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.67.

Hedge Funds Weigh In On Acrivon Therapeutics

A number of institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in Acrivon Therapeutics during the 4th quarter worth $40,000. Wealthedge Investment Advisors LLC bought a new stake in Acrivon Therapeutics during the 4th quarter valued at approximately $65,000. Corton Capital Inc. acquired a new stake in Acrivon Therapeutics in the 4th quarter valued at approximately $73,000. American Century Companies Inc. grew its holdings in Acrivon Therapeutics by 14.2% in the 4th quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock valued at $106,000 after buying an additional 2,186 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Acrivon Therapeutics by 20.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company’s stock worth $223,000 after buying an additional 6,239 shares during the period. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Stock Performance

Shares of ACRV stock opened at $5.44 on Monday. The stock’s 50 day simple moving average is $5.62 and its 200 day simple moving average is $6.80. Acrivon Therapeutics has a twelve month low of $4.69 and a twelve month high of $11.90. The company has a market capitalization of $169.38 million, a price-to-earnings ratio of -2.01 and a beta of 0.85.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.